Video

Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer

Author(s):

Joshua Bauml, MD

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Related Content
Toripalimab Plus Chemo for Nasopharyngeal Carcinoma and ESCC | Image Credit: © Cornflakesei - stock.adobe.com
November 18th 2024

Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
November 22nd 2021

Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson

lertsakwiman– stock.adobe.com
November 12th 2024

Selumetinib Boosts ORR in NF1 With Inoperable Plexiform Neurofibroma

IMA203 in Melanoma
November 11th 2024

IMA203 Produces Responses in Heavily Pretreated Advanced Melanoma, Other Solid Tumors